Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 15/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.48 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.48 |
| ▸ | GCK | P35557 | 2/20 | 0.42 |
| ▸ | RARA | P10276 | 1/20 | 0.40 |
| ▸ | RARB | P10826 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13875664 | 0.88 | CCNB2 (0.51) | CCNB2CDK1CCNB1CCNB3GCK | |
| SCHEMBL4181761 | 0.87 | RIPK1 (0.52) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL2086747 | 0.84 | PRMT5 (0.41) | GCKRARARARBCYP3A4PRMT5 | |
| SCHEMBL14115572 | 0.78 | RIPK1 (0.61) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL4186396 | 0.78 | GCK (0.53) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL9071271 | 0.78 | GCK (0.53) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL2668031 | 0.76 | GCK (0.37) | RIPK1GCKRARARARBPRMT5 | |
| SCHEMBL2087030 | 0.76 | GCK (0.46) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL2087106 | 0.76 | GCK (0.38) | GCKRARARARBCYP3A4PRMT5 | |
| SCHEMBL2086138 | 0.76 | AURKA (0.39) | CCNB2CDK1CCNB1CCNB3GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105263-A1 | HETEROBICYCLIC COMPOUNDS AS GLUCOKINASE ACTIVATORS | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | claimed |
| US-20090105263-A1 | HETEROBICYCLIC COMPOUNDS AS GLUCOKINASE ACTIVATORS | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105263-A1 | HETEROBICYCLIC COMPOUNDS AS GLUCOKINASE ACTIVATORS | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105263-A1 | HETEROBICYCLIC COMPOUNDS AS GLUCOKINASE ACTIVATORS | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105263-A1 | HETEROBICYCLIC COMPOUNDS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | RIPK1 895/4885CCNB2 824/4885CDK1 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.